Literature DB >> 34910352

Androgenetic alopecia and COVID-19: Is there a clinical connection?

Moein Baghani1, Mohammad Reza Pourani1, Sayyed Mojtaba Nekooghadam2,3, Davood Ommi2,4, Alireza Fatemi2,5, Fahimeh Abdollahimajd1,2, Hamideh Moravvej1.   

Abstract

BACKGROUND: During the coronavirus disease 2019 (COVID-19) outbreak, multiple studies showed higher rates of severe infection in adults and specifically in male patients, which may be related to differences in androgen receptor (AR) expression. Androgenetic alopecia (AGA) is one of the AR expression manifestations. AIM: To explore AGA severity as a possible risk factor for COVID-19 severity in hospitalized patients.
METHODS: A total of 164 subjects (116 men and 48 females) with confirmed COVID-19 in need of hospitalization were included in this study. An experienced dermatologist examined the correlation of clinical signs of COVID-19 severity with AGA types. For evaluation of the association between categorical variables and comparison of the mean age in three groups of COVID-19 patients, the Fisher's exact test and the analysis of variance were used.
RESULTS: Our cross-sectional study included 116 male patients (70.7%) with a median age of 65.5 (age range: 22-97) years. Among them, 13.8% required intubation, 15.5% needed intensive care unit (ICU) care, and 70.7% required inward hospitalization. The Hamilton-Norwood Scale (HNS) was as follows: HNS I 14.7%, HNS II 12.1%, HNS III 20.7%, HNS IV 19.8%, HNS IV 29.8%, HNS V 17.2%, HNS VI 13.8%, and HNS VII 1.7%. Also, 29.3% of the patients were female, possessing a median age of 72 (age range: 23-98) years. In this group, 8.3% required intubation, 6.3% required ICU care, and 85.4% needed inpatient ward admission care. The Ludwig Scale (LS) was as follows: LS I 52.1%, LS II 35.4%, and LS III 12.5%.
CONCLUSION: The severity of AGA type did not correlate with the severity of COVID-19 among hospitalized patients. Our results were in contrast with other research that suggested AGA severity as a marker of unfavorable outcomes of COVID-19.
© 2021 Wiley Periodicals LLC.

Entities:  

Keywords:  COVID-19; SARS-CoV-2 infection; androgenetic alopecia; population at risk; risk factors; treatment

Mesh:

Substances:

Year:  2021        PMID: 34910352     DOI: 10.1111/jocd.14670

Source DB:  PubMed          Journal:  J Cosmet Dermatol        ISSN: 1473-2130            Impact factor:   2.696


  2 in total

Review 1.  Comorbidities in Androgenetic Alopecia: A Comprehensive Review.

Authors:  Shuang Chen; Xiaohang Xie; Guoqiong Zhang; Yong Zhang
Journal:  Dermatol Ther (Heidelb)       Date:  2022-09-17

Review 2.  Examining Male Predominance of Severe COVID-19 Outcomes: A Systematic Review.

Authors:  David K Twitchell; Michael B Christensen; Geoffrey Hackett; Abraham Morgentaler; Farid Saad; Alexander W Pastuszak
Journal:  Androg Clin Res Ther       Date:  2022-07-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.